Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
A new investigational drug, cizutamig, is showing early promise for generalized myasthenia gravis (gMG). In a phase 1b trial, all 12 patients dosed across the first two cohorts met responder criteria, with rapid and sustained symptom improvement — and zero cases of cytokine release syndrome. It's early days, but the results are encouraging for the neuromuscular disease space.
A new investigational bispecific antibody called cizutamig is generating interest in the myasthenia gravis (MG) world. Developed by UCB (acquired via a $2.2B deal with Candid Therapeutics), cizutamig is a BCMA×CD3 T-cell engager designed to deplete the immune cells that produce the pathogenic autoantibodies driving generalized MG (gMG). Interim phase 1b data, presented at the 2026 AANEM Annual Meeting, showed all 12 patients dosed across the first two cohorts met the trial's responder criteria — with rapid, sustained improvements in both disease severity and daily functioning.
What makes this especially notable is the safety profile. No cytokine release syndrome (CRS), no immune effector cell-associated neurotoxicity, and all treatment-emergent adverse events were grade 2 or lower — a meaningful finding for T-cell engager therapies, which have historically raised safety concerns in other settings.
By the Numbers:
Why it matters: gMG is notoriously heterogeneous — no single treatment works for everyone. Cizutamig targets B cells upstream, before they mature into antibody-producing plasma cells, potentially offering a new mechanism of action for patients who don't respond to existing therapies.
